Barer & Son Capital
VC Fund
Mendham, United States
Barer & Son Capital is a venture capital firm that seeks to invest in the healthcare and life science sector. The firm was founded in 2017 and is based in Mendham, New Jersey.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Barer & Son Capital invests in
Stages Barer & Son Capital invests in
Countries Barer & Son Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joshua Barer
|
|||
Investment Focus
Industry
- Biotechnology 2 (67%)
- Health Diagnostics 2 (67%)
- Medical 1 (33%)
- Wellness 1 (33%)
- Biopharma 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
- Convertible Note 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joshua Barer
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $35M / Series A / Jun 24, 2020 | |
Viela Bio
|
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integratedbiotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland. | $75M / Series B / Jun 18, 2019 | |
|
AsclepiX Therapeutics
|
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M / Convertible Note / Nov 13, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Barer & Son Capital invest in?
Barer & Son Capital invests primarily in Biotechnology, Health Diagnostics and Medical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Barer & Son Capital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Barer & Son Capital?
The team at Barer & Son Capital includes Joshua Barer (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
